You are here

Home

Vaccines

Primary tabs

Thu, 2015-01-08 20:48 — mdmcdonald
Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Add Content to this group

Click to add a new Group Post Simple to this group
Click to add a new Group Post Simple w Images to this group
Click to add a new Group Post to this group
Click to add a new PRIVATE Group Post to this group
Click to add a new TASK to this group

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft
Subscribe to group

Email address for group

vaccines_global@m.resiliencesystem.org

AP roundup: U.S. official expects quick vaccine distribution, International developments

Fri, 2020-11-20 10:18 — mike kraft
The Latest: U.S. official expects quick vaccine distribution WASHINGTON — Gen. Gustave Perna of the Trump administration’s Operation Warp Speed vaccine program says about 40 million doses could be ready for distribution in the U.S. quickly if the Food and... AP NEWS
 
Country / Region Tags: 
China
Europe
Global
Greece
South Korea
SouthEast Asia
Sri Lanka
United States
US - Hawaii
General Topic Tags: 
COVID-19
Data
Contagion
Drought
Health
Pandemics
Transportation
Problem, Solution, SitRep, or ?: 
Situation Report

The Vaccines Will Probably Work. Making Them Fast Will Be the Hard Part.

Wed, 2020-11-18 13:48 — mike kraft

The promising news that not just one but two coronavirus vaccines were more than 90 percent effective in early results has buoyed hopes that an end to the pandemic is in sight.

But even if the vaccines are authorized soon by federal regulators — the companies developing them have said they expect to apply soon — only a sliver of the American public will be able to get one by the end of the year. The two companies, Pfizer and Moderna, have estimated they will have 45 million doses, or enough to vaccinate 22.5 million Americans, by January.

Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Government
Pandemics
Science
Technology
Problem, Solution, SitRep, or ?: 
Situation Report

Pharma trade group issues guidelines for improving diversity of clinical trial participants

Wed, 2020-11-18 10:14 — mike kraft
PhRMA issues guidelines for improving clinical trial diversity - STAT PhRMA released guidelines on Tuesday to enhance racial and ethnic diversity among participants in clinical trials. Nicholas St. Fleur STAT
Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Contagion
Demographics
Disease
Health
Pandemics
Research
Problem, Solution, SitRep, or ?: 
Situation Report

Pfizer ends vaccine trial with 95% success rate, paving way for a shot this year

Wed, 2020-11-18 08:49 — mike kraft
Pfizer ends vaccine trial with 95% success rate, paving way for a shot this year Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday. Michael Erman U.S.
Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Disease
Health
Pandemics
Research
Problem, Solution, SitRep, or ?: 
Situation Report

WHO tempers prospect of a coronavirus vaccine with warning of a long distribution fight to come

Mon, 2020-11-16 19:33 — mike kraft
WHO tempers prospect of a coronavirus vaccine with warning of a long fight to come Finding a coronavirus vaccine is like building a base camp on Mount Everest, not reaching the summit, the WHO says. Adam Taylor Washington Post
Country / Region Tags: 
Africa
Global
SouthEast Asia
United Nations
General Topic Tags: 
COVID-19
Contagion
Disease
Government
Health
Pandemics
Research
Science
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Pfizer vs Moderna vaccines: What we know, and what we don't

Mon, 2020-11-16 19:21 — mike kraft
Pfizer vs Moderna vaccines: What we know, and what we don't Two vaccine candidates using similar technology are winning the COVID-19 vaccine race in the U.S., and in the process validating the mRNA platform — which is yet untested on the market— as well as setting the path for vaccine makers to follow in order to block the virus. YahooNews
Country / Region Tags: 
Europe
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Disease
Health
Pandemics
Research
Science
Problem, Solution, SitRep, or ?: 
Analysis

Moderna, 2nd virus vaccine shows overwhelming success in U.S. tests

Mon, 2020-11-16 10:26 — mike kraft
2nd virus vaccine shows overwhelming success in U.S. tests Moderna said Monday its COVID-19 vaccine is proving to be highly effective in a major trial, a second dash of hope in the global race for a shot to tame a resurgent virus that is now killing more... AP NEWS

Moderna said Monday its COVID-19 vaccine is proving to be highly effective in a major trial, a second dash of hope in the global race for a shot to tame a resurgent virus that is now killing more than 8,000 people a day worldwide.

Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Disease
Health
Pandemics
Research
Problem, Solution, SitRep, or ?: 
Situation Report

States waiting for answers from feds on coronavirus vaccine distribution

Sat, 2020-11-14 11:10 — mike kraft
States waiting for answers from feds on coronavirus vaccine distribution With the US on the cusp of a coronavirus vaccine, states are scrambling to nail down their distribution plans as they await key information -- like how many doses of the vaccine they'll receive. Priscilla Alvarez, Sara Murray and Elizabeth Cohen, CNN CNN
Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Contagion
Disease
Government
Health
Policy
Problem, Solution, SitRep, or ?: 
Situation Report

How Pfizer Plans to Distribute Its Vaccine (It’s Complicated)

Fri, 2020-11-13 15:24 — mike kraft

For months, scientists and public health experts have been saying the most crucial part of defusing the Covid-19 pandemic will be developing a safe and effective vaccine. So it was cause for celebration this week when Pfizer announced that an early analysis showed its vaccine candidate was more than 90 percent effective.

Now the drug maker, the government and the public health community face a new challenge: quickly making millions of doses of the vaccine and getting them to the hospitals, clinics and pharmacies where they will be injected, two separate times, into people’s arms.

Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Disease
Economics
Government
Health
Pandemics
Policy
Problem, Solution, SitRep, or ?: 
Problem
Situation Report

Why Poorer Countries Aren't Likely To Get The Pfizer Vaccine Any Time Soon

Fri, 2020-11-13 14:58 — mike kraft

This week, the world heard encouraging news about a vaccine for COVID-19.

On Monday, the pharmaceutical company Pfizer, and its partner BioNTech, said their experimental vaccine appears to work – and work quite well. A preliminary analysis suggests the vaccine is more than 90 percent effective at preventing COVID-19 symptoms.

Health officials hope to start vaccinating some Americans in a few months.

"The vaccine is on its way, folks," Dr. Anthony Fauci told a crowd Tuesday, via video link, outside Brooklyn Borough Hall.

But what about the rest of world, especially people in poorer counties. Is the vaccine "on its way for them?"

Country / Region Tags: 
Africa
Germany
Global
Middle East
SouthEast Asia
United States
General Topic Tags: 
COVID-19
Capacity
Complexity
Contagion
Disease
Health
Pandemics
Problem, Solution, SitRep, or ?: 
Problem
Situation Report

Pages

howdy folks
Page loaded in 0.906 seconds.